ALLUVI: A IN-DEPTH EXAMINATION INTO RETATRUTIDE'S POSSIBILITIES

Alluvi, previously BI 4744, offers a promising breakthrough in obesity therapy. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive results in research studies, potentially exceeding current GLP-1 site agonists